Furthermore, earlier studies have shown that tumors with greater mutational loads, expressing more tumor-specific antigens that induce larger amplitude of neoantigen-specific CD8+ T cell responses, are more sensitive to anti-PD-1 therapy, such as non-small cell lung cancer [204]. The gene discussed is CD8A; the disease is neoplasm.